News
AXDX
0.9453
+1.54%
0.0143
Weekly Report: what happened at AXDX last week (0415-0419)?
Weekly Report · 4d ago
Weekly Report: what happened at AXDX last week (0408-0412)?
Weekly Report · 04/15 10:26
ACCELERATE DIAGNOSTICS INC -ACCELERATE DIAGNOSTICS ANNOUNCES 510(K) SUBMISSION OF ACCELERATE ARC™ SYSTEM TO FDA
Reuters · 04/09 22:07
Weekly Report: what happened at AXDX last week (0401-0405)?
Weekly Report · 04/08 10:30
Accelerate Diagnostics Price Target Cut to $1.00/Share From $2.00 by Craig-Hallum
Dow Jones · 04/01 18:11
Accelerate Diagnostics Is Maintained at Hold by Craig-Hallum
Dow Jones · 04/01 18:11
Craig-Hallum Maintains Hold on Accelerate Diagnostics, Lowers Price Target to $1
Benzinga · 04/01 18:00
Analysts Have Conflicting Sentiments on These Healthcare Companies: Staar Surgical (STAA), DarioHealth (DRIO) and Accelerate Diagnostics (AXDX)
TipRanks · 04/01 12:40
ACCELERATE DIAGNOSTICS, INC. <AXDX.O> : CRAIG-HALLUM CUTS TARGET PRICE TO $1.5 FROM $2
Reuters · 04/01 11:05
Weekly Report: what happened at AXDX last week (0325-0329)?
Weekly Report · 04/01 10:29
Stockholders Beware: Accelerate Diagnostics’ Surge in Authorized Shares Signals Potential Dilution Risk
TipRanks · 03/30 06:01
Accelerate Diagnostics Inc reports results for the quarter ended in December - Earnings Summary
Accelerate Diagnostics Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 81 cents per share. Revenue rose 1.9% to $3.03 million from a year ago. Accelerate Diagnostic Inc shares had fallen by 74.2% this quarter.
Reuters · 03/29 19:54
Accelerate Diagnostics (AXDX) Reports Q4 Loss, Misses Revenue Estimates
NASDAQ · 03/28 21:45
Recap: Accelerate Diagnostics Q4 Earnings
Accelerate Diagnostics reported its Q4 earnings on March 28, 2024. The company missed estimates by -44.0% and missed on revenue by $55 thousand. Accelerate Diagnostic is expected to announce its earnings on April 28. Last quarter the company missed on EPS by $0.11.
Benzinga · 03/28 21:15
Accelerate Diagnostics GAAP EPS of -$0.89 misses by $0.27, revenue of $3M misses by $0.45M
Earnings News Accelerate Diagnostics GAAP EPS of -$0.89 misses by $0.27, revenue of $3M misses by Q4 GAAP revenue of $3 million misses by  $0 45 million. Accelerate diagnostics, Inc. (AXDX) expected to report Q4 results on March 28, 2024.
Seeking Alpha · 03/28 20:16
*Accelerate Diagnostics 4Q R&D Expenses $5.6M >AXDX
Dow Jones · 03/28 20:14
*Accelerate Diagnostics 4Q Loss/Shr 89c >AXDX
Dow Jones · 03/28 20:14
*Accelerate Diagnostics 4Q Sales $3M >AXDX
Dow Jones · 03/28 20:14
Press Release: Accelerate Diagnostics Reports -2-
Three months ended December 31, 2015, the company reported a total of $1.2 billion in sales. The company's total sales for the quarter was $23.9 billion. In the first quarter of 2016, sales were $21.7 billion. Sales are expected to rise to $28.5 billion by the end of the year.
Dow Jones · 03/28 20:06
BRIEF-Accelerate Diagnostics Q4 Sales USD 3 Million
Reuters · 03/28 20:05
More
Webull provides a variety of real-time AXDX stock news. You can receive the latest news about Accelerate Diagnostics Inc through multiple platforms. This information may help you make smarter investment decisions.
About AXDX
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions for the global challenges of antibiotic resistance and sepsis. Its Accelerate Pheno system and Accelerate PhenoTest BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the optimal antibiotic therapy for deadly infections. The United States Food and Drug Administration (FDA) cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately seven hours direct from positive blood cultures. The Accelerate PhenoTest BC Kit, which is the first test kit for the system, is indicated as an aid, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia and fungemia, both life-threatening conditions with high morbidity and mortality risk. Its other products include Accelerate Arc system and BC Kit (Accelerate Arc Products) and Accelerate Wave system.